Carisma Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview

Carisma Therapeutics

06/08/2024 12:07

* Carisma Therapeutics Inc  CARM.OQ   CARM.O  is expected
to show
a rise in quarterly revenue when it reports  results on August 8
(estimated) for the period ending June 30 2024
    * The Cambridge Massachusetts-based  company is expected to
report
a 10.3% increase in revenue to $3.925 million from $3.56 million
a year ago, according to the mean estimate from 4 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Carisma Therapeutics Inc
is
for a loss of 30 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Carisma
Therapeutics Inc is $8.00​, above​ its last closing price
of $0.89. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.47       -0.43      -0.46     Missed  -6.4
 Dec. 31 2024              -0.55      -0.52     Beat    5.9
 Sep. 30 2023  -0.56       -0.57      -0.53     Beat    7​
 Jun. 30 2023  -0.60       -0.60      -0.49     Beat    17.9
 ​​Mar.        -0.89       -0.89      -1.93     Missed  -116.9
 31 2023                                                
 Dec. 31 2022  -2.20       -2.20      -0.80     Beat    63.6​
 Sep. 30 2022  -1.60       -1.60      2.00      Beat    225
 Jan. 1 0001   -2.60       -2.60      -3.20     Missed  -23.1
 This summary was machine generated August 6 at 11:07 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)